These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34488801)

  • 21. The Global Fund's paradigm of oversight, monitoring, and results in Mozambique.
    Warren A; Cordon R; Told M; de Savigny D; Kickbusch I; Tanner M
    Global Health; 2017 Dec; 13(1):89. PubMed ID: 29233165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug discovery and beyond: the role of public-private partnerships in improving access to new malaria medicines.
    Nwaka S
    Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S20-9. PubMed ID: 16085175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research.
    Verbaanderd C; Rooman I; Huys I
    Trials; 2021 May; 22(1):322. PubMed ID: 33947441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innovative financing for late-stage global health research and development: the Global Health Investment Fund.
    Fitchett JR; Fan Li J; Atun R
    Int Health; 2016 Jan; 8(1):3-4. PubMed ID: 26612852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
    Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
    Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementing the global plan to stop TB, 2011-2015--optimizing allocations and the Global Fund's contribution: a scenario projections study.
    Korenromp EL; Glaziou P; Fitzpatrick C; Floyd K; Hosseini M; Raviglione M; Atun R; Williams B
    PLoS One; 2012; 7(6):e38816. PubMed ID: 22719954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An alternative mechanism for international health aid: evaluating a Global Social Protection Fund.
    Basu S; Stuckler D; McKee M
    Health Policy Plan; 2014 Jan; 29(1):127-36. PubMed ID: 23335466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Public-Private Partnerships and the Landscape of Neglected Tropical Disease Research: The Shifting Logic and Spaces of Knowledge Production.
    Ferpozzi H
    Minerva; 2023 Jun; ():1-23. PubMed ID: 37359299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Partnership Activity for Neglected Tropical Diseases].
    Akao Y; Ochida A; Muranishi H; Nomura I; Ichikawa T
    Yakugaku Zasshi; 2022; 142(7):697-701. PubMed ID: 35781496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Global Fund's resource allocation decisions for HIV programmes: addressing those in need.
    Avdeeva O; Lazarus JV; Aziz MA; Atun R
    J Int AIDS Soc; 2011 Oct; 14():51. PubMed ID: 22029667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leveraging Global Fund investments for health systems strengthening: a qualitative case study on Morocco's Concept Note development.
    Bolan N; Azzouzi A; Alami K; Alaoui A; Hachri H; Latifi A; Ferenchick E; Mangiaterra V; Murray S; Shakarishvili G; Souteyrand Y
    East Mediterr Health J; 2020 Aug; 26(8):957-966. PubMed ID: 32896891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases.
    Douglas CMW; Aith F; Boon W; de Neiva Borba M; Doganova L; Grunebaum S; Hagendijk R; Lynd L; Mallard A; Mohamed FA; Moors E; Oliveira CC; Paterson F; Scanga V; Soares J; Raberharisoa V; Kleinhout-Vliek T
    Orphanet J Rare Dis; 2022 Sep; 17(1):344. PubMed ID: 36064440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bibliometric study of research and development for neglected diseases in the BRICS.
    Bai J; Li W; Huang YM; Guo Y
    Infect Dis Poverty; 2016 Sep; 5(1):89. PubMed ID: 27595987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Corporate Efforts to Research and Develop Therapeutic Agents for Infectious Diseases That Threaten Human].
    Yoshida R; Kaki R; Yoshida O; Shishido T; Kato T; Yamano Y
    Yakugaku Zasshi; 2022; 142(7):691-696. PubMed ID: 35781495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Essential and non-essential drugs marketed by the 20 largest European pharmaceutical companies in developing countries.
    Hartog R
    Soc Sci Med; 1993 Oct; 37(7):897-904. PubMed ID: 8211308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "It's About the Idea Hitting the Bull's Eye": How Aid Effectiveness Can Catalyse the Scale-up of Health Innovations.
    Wickremasinghe D; Gautham M; Umar N; Berhanu D; Schellenberg J; Spicer N
    Int J Health Policy Manag; 2018 Aug; 7(8):718-727. PubMed ID: 30078292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Public-private partnership: from there to here.
    Croft SL
    Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic review of strategies to increase access to health services among children over five in low- and middle-income countries.
    Bright T; Felix L; Kuper H; Polack S
    Trop Med Int Health; 2018 May; 23(5):476-507. PubMed ID: 29473273
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.